Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Efficacy of ciclesonide in the treatment of patients with asthma exacerbation.

Zietkowski Z, Lukaszyk M, Skiepko R, Budny W, Skiepko U, Jóźwik A, Bodzenta-Lukaszyk A.

Postepy Dermatol Alergol. 2019 Apr;36(2):217-222. doi: 10.5114/ada.2019.84596. Epub 2019 May 14.

2.

Polish Society of Allergology statement on the diagnosis and treatment of severe, difficult-to-control bronchial asthma.

Kupczyk M, Bartuzi Z, Bodzenta-Łukaszyk A, Kulus M, Kuna P, Kupryś-Lipińska I, Mazurek H.

Postepy Dermatol Alergol. 2019 Apr;36(2):147-157. doi: 10.5114/ada.2019.84591. Epub 2019 May 14.

3.

Diagnosis of solitary extramedullary plasmacytoma located in the nasopharynx in a patient with acquired angioedema.

Czaban M, Moniuszko M, Klimek M, Lukaszyk M, Rozanska M, Reszec J, Rogowski M, Bodzenta-Lukaszyk A.

Postepy Dermatol Alergol. 2018 Dec;35(6):636-637. doi: 10.5114/ada.2018.77616. Epub 2018 Nov 13. No abstract available.

4.

Markers of anaphylaxis - a systematic review.

Tomasiak-Łozowska MM, Klimek M, Lis A, Moniuszko M, Bodzenta-Łukaszyk A.

Adv Med Sci. 2018 Sep;63(2):265-277. doi: 10.1016/j.advms.2017.12.003. Epub 2018 Mar 20.

PMID:
29486376
5.

Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease.

Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J.

Int Urol Nephrol. 2018 Jan;50(1):121-125. doi: 10.1007/s11255-017-1741-5. Epub 2017 Nov 13.

6.

Comment on "Calcium preparations do not inhibit allergic reactions: a randomized controlled trial".

Bodzenta-Łukaszyk A, Łukaszyk M.

Pol Arch Intern Med. 2017 Sep 29;127(9):577-578. doi: 10.20452/pamw.4105. Epub 2017 Sep 29. No abstract available.

7.

Fibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?

Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J.

Arch Med Sci. 2017 Jun;13(4):845-850. doi: 10.5114/aoms.2016.58647. Epub 2016 Mar 17.

8.

Asthma is associated with reduced fibrinolytic activity, abnormal clot architecture, and decreased clot retraction rate.

Tomasiak-Lozowska MM, Misztal T, Rusak T, Branska-Januszewska J, Bodzenta-Lukaszyk A, Tomasiak M.

Allergy. 2017 Feb;72(2):314-319. doi: 10.1111/all.13054. Epub 2016 Oct 14.

PMID:
27659252
9.

High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers.

Boonpiyathad T, Meyer N, Moniuszko M, Sokolowska M, Eljaszewicz A, Wirz OF, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A, Ruxrungtham K, van de Veen W.

Allergy. 2017 Mar;72(3):407-415. doi: 10.1111/all.12966. Epub 2016 Jul 20.

PMID:
27341567
10.

Reduced clot retraction rate and altered platelet energy production in patients with asthma.

Tomasiak-Lozowska MM, Rusak T, Misztal T, Bodzenta-Lukaszyk A, Tomasiak M.

J Asthma. 2016 Aug;53(6):589-98. doi: 10.3109/02770903.2015.1130151. Epub 2016 May 4.

PMID:
27145190
11.

GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients.

Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J.

Int Urol Nephrol. 2016 Jun;48(6):839-44. doi: 10.1007/s11255-016-1278-z. Epub 2016 Apr 4.

12.

Enhanced pretreatment CD25 expression on peripheral blood CD4+ T cell predicts shortened survival in acute myeloid leukemia patients receiving induction chemotherapy.

Bołkun Ł, Rusak M, Eljaszewicz A, Pilz L, Radzikowska U, Łapuć I, Łuksza E, Dąbrowska M, Bodzenta-Łukaszyk A, Kłoczko J, Moniuszko M.

Pharmacol Rep. 2016 Feb;68(1):12-9. doi: 10.1016/j.pharep.2015.05.025. Epub 2015 Jun 10.

PMID:
26721345
13.

The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.

Bartuzi Z, Bodzenta-Łukaszyk A, Kuna P, Kupryś-Lipińska I, Niżankowska-Mogilnicka E, Samoliński B.

Pneumonol Alergol Pol. 2015;83(4):335-8. doi: 10.5603/PiAP.2015.0053. No abstract available.

14.

The statement of the Polish Society of Allergology experts on the treatment of difficult-to-treat asthma.

Bodzenta-Łukaszyk A, Fal AM, Jassem E, Kowalski ML, Kuna P, Kupczyk M.

Pneumonol Alergol Pol. 2015;83(4):324-34. doi: 10.5603/PiAP.2015.0052.

15.

Iron Status and Inflammation in Early Stages of Chronic Kidney Disease.

Łukaszyk E, Łukaszyk M, Koc-Żórawska E, Tobolczyk J, Bodzenta-Łukaszyk A, Małyszko J.

Kidney Blood Press Res. 2015;40(4):366-73. doi: 10.1159/000368512. Epub 2015 Jun 20.

16.

Prognostic significance of PD-1 expression on peripheral blood CD4+ T cells in patients with newly diagnosed chronic lymphocytic leukemia.

Rusak M, Eljaszewicz A, Bołkun Ł, Łuksza E, Łapuć I, Piszcz J, Singh P, Dąbrowska M, Bodzenta-Łukaszyk A, Kłoczko J, Moniuszko M.

Pol Arch Med Wewn. 2015;125(7-8):553-9. Epub 2015 Jul 3.

17.

Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.

Lapuc I, Bolkun L, Eljaszewicz A, Rusak M, Luksza E, Singh P, Miklasz P, Piszcz J, Ptaszynska-Kopczynska K, Jasiewicz M, Kaminski K, Dabrowska M, Bodzenta-Lukaszyk A, Kloczko J, Moniuszko M.

Oncol Rep. 2015 Sep;34(3):1269-78. doi: 10.3892/or.2015.4088. Epub 2015 Jun 26.

PMID:
26135617
18.

Vitamin D3 Treatment Decreases Frequencies of CD16-Positive and TNF-α-Secreting Monocytes in Asthmatic Patients.

Grubczak K, Lipinska D, Eljaszewicz A, Singh P, Radzikowska U, Miklasz P, Dabrowska M, Jablonska E, Bodzenta-Lukaszyk A, Moniuszko M.

Int Arch Allergy Immunol. 2015;166(3):170-6. doi: 10.1159/000380882. Epub 2015 Apr 11.

19.

Endothelial progenitor cell levels in juvenile idiopathic arthritis patients: effects of anti-inflammatory therapies.

Rusak M, Radzikowska U, Glowinska-Olszewska B, Dobrenko E, Piotrowska-Jastrzebska J, Dabrowska M, Bodzenta-Lukaszyk A, Bossowski A, Moniuszko M.

Pediatr Rheumatol Online J. 2015 Feb 19;13:6. doi: 10.1186/s12969-015-0001-4. eCollection 2015.

20.

Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation.

Skiepko R, Ziętkowski Z, Lukaszyk M, Budny W, Skiepko U, Milewski R, Bodzenta-Łukaszyk A.

Postepy Dermatol Alergol. 2014 Oct;31(5):305-9. doi: 10.5114/pdia.2014.40973. Epub 2014 Oct 22.

21.

Pharmacological consequences of inhaled drug delivery to small airways in the treatment of asthma.

Bodzenta-Łukaszyk A, Kokot M.

Adv Ther. 2014 Aug;31(8):803-16. doi: 10.1007/s12325-014-0143-7. Epub 2014 Aug 13. Review.

PMID:
25116888
22.

Development of asthmatic response upon bronchial allergen challenge is associated with dynamic changes of interleukin-10-producing and interleukin-10-responding CD4+ T cells.

Moniuszko M, Grubczak K, Kowal K, Eljaszewicz A, Rusak M, Jeznach M, Jablonska E, Dabrowska M, Bodzenta-Lukaszyk A.

Inflammation. 2014 Dec;37(6):1945-56. doi: 10.1007/s10753-014-9927-9.

23.

The effect of inhaled corticosteroids on the concentration of soluble CD163 in induced sputum of allergic asthma patients.

Kowal K, Moniuszko M, Bodzenta-Lukaszyk A.

J Investig Allergol Clin Immunol. 2014;24(1):49-55.

24.

Omalizumab treatment in brittle asthma.

Skiepko R, Zietkowski Z, Skiepko U, Budny W, Lukaszyk M, Bodzenta-Lukaszyk A.

Postepy Dermatol Alergol. 2014 Feb;31(1):36-8. doi: 10.5114/pdia.2014.40658. Epub 2014 Feb 25.

25.

Delayed diagnosis of human immunodeficiency virus infection in a patient with non-specific neurological symptoms and pancytopenia: a case report.

Moniuszko M, Moniuszko A, Puciłowska J, Kisluk K, Jeznach M, Grzeszczuk A, Flisiak R, Bodzenta-Lukaszyk A.

J Med Case Rep. 2014 Mar 24;8:104. doi: 10.1186/1752-1947-8-104.

26.

Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension.

Jasiewicz M, Kowal K, Kowal-Bielecka O, Knapp M, Skiepko R, Bodzenta-Lukaszyk A, Sobkowicz B, Musial WJ, Kaminski KA.

Cytokine. 2014 Mar;66(1):40-5. doi: 10.1016/j.cyto.2013.12.013. Epub 2014 Jan 14.

PMID:
24548423
27.

Decreased CD127 expression on CD4+ T-cells and elevated frequencies of CD4+CD25+CD127- T-cells in children with long-lasting type 1 diabetes.

Moniuszko M, Glowinska-Olszewska B, Rusak M, Jeznach M, Grubczak K, Lipinska D, Milewski R, Milewska AJ, Dabrowska M, Jablonska E, Kretowski A, Gorska M, Bodzenta-Lukaszyk A, Bossowski A.

Clin Dev Immunol. 2013;2013:459210. doi: 10.1155/2013/459210. Epub 2013 Nov 21.

28.

Echinococcus multilocularis infection in a patient treated with omalizumab.

Skiepko R, Zietkowski Z, Skiepko U, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A.

J Investig Allergol Clin Immunol. 2013;23(3):199-200. No abstract available.

29.

Glucocorticoids upregulate decreased IL-7 receptor expression in asthmatic patients and simian immunodeficiency virus-infected non-human primates.

Moniuszko M, Lipinska D, Jeznach M, Kowal K, Grubczak K, Rusak M, McKinnon K, Vaccari M, Liyanage NP, Fenizia C, Wawrusiewicz-Kurylonek N, Dabrowska M, Jablonska E, Kretowski A, Gorska M, Bodzenta-Lukaszyk A.

J Biol Regul Homeost Agents. 2013 Apr-Jun;27(2):427-42.

PMID:
23830393
30.

Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.

Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Seitz MJ, Aberer W, Bodzenta-Lukaszyk A, Bonifazi F, Campi P, Darsow U, Haeberli G, Hawranek T, Küchenhoff H, Lang R, Quercia O, Reider N, Schmid-Grendelmeier P, Severino M, Sturm GJ, Treudler R, Wüthrich B.

PLoS One. 2013 May 20;8(5):e63233. doi: 10.1371/journal.pone.0063233. Print 2013.

31.

Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial.

Bodzenta-Lukaszyk A, van Noord J, Schröder-Babo W, McAulay K, McIver T.

Curr Med Res Opin. 2013 May;29(5):579-88. doi: 10.1185/03007995.2013.772506. Epub 2013 Feb 20.

PMID:
23368897
32.

Phenotypic correlations between monocytes and CD4+ T cells in allergic patients.

Moniuszko M, Kowal K, Jeznach M, Rusak M, Dabrowska M, Bodzenta-Lukaszyk A.

Int Arch Allergy Immunol. 2013;161(2):131-41. doi: 10.1159/000343687. Epub 2013 Jan 23.

PMID:
23343753
33.

Lower proportions of CD4+CD25(high) and CD4+FoxP3, but not CD4+CD25+CD127(low) FoxP3+ T cell levels in children with autoimmune thyroid diseases.

Bossowski A, Moniuszko M, Dąbrowska M, Sawicka B, Rusak M, Jeznach M, Wójtowicz J, Bodzenta-Lukaszyk A, Bossowska A.

Autoimmunity. 2013 May;46(3):222-30. doi: 10.3109/08916934.2012.751981. Epub 2013 Jan 22.

PMID:
23249428
34.

[Evaluation of CD4+CD161+CD196+ and CD4+IL-17+ Th17 cells in the peripheral blood of young patients with Hashimoto's thyroiditis and Graves' disease].

Bossowski A, Moniuszko M, Idźkowska E, Dąbrowska M, Jeznach M, Sawicka B, Borysewicz-Sańczyk H, Bossowska A, Rusak M, Bodzenta-Łukaszyk A.

Pediatr Endocrinol Diabetes Metab. 2012;18(3):89-95. Polish.

PMID:
23146786
35.

Relationship between circulating endothelial progenitor cells and endothelial dysfunction in children with type 1 diabetes: a novel paradigm of early atherosclerosis in high-risk young patients.

Głowińska-Olszewska B, Moniuszko M, Hryniewicz A, Jeznach M, Rusak M, Dąbrowska M, Łuczyński W, Bodzenta-Łukaszyk A, Bossowski A.

Eur J Endocrinol. 2013 Jan 17;168(2):153-61. doi: 10.1530/EJE-12-0857. Print 2013 Feb.

PMID:
23111589
36.

Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.

Bodzenta-Lukaszyk A, Buhl R, Balint B, Lomax M, Spooner K, Dissanayake S.

J Asthma. 2012 Dec;49(10):1060-70. doi: 10.3109/02770903.2012.719253. Epub 2012 Oct 26.

PMID:
23102189
37.

Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study.

Aalbers R, Brusselle G, McIver T, Grothe B, Bodzenta-Lukaszyk A.

Adv Ther. 2012 Nov;29(11):958-69. doi: 10.1007/s12325-012-0058-0. Epub 2012 Oct 17.

PMID:
23081745
38.

Inflammatory markers and acid-base equilibrium in exhaled breath condensate of stable and unstable asthma patients.

Tomasiak-Lozowska MM, Zietkowski Z, Przeslaw K, Tomasiak M, Skiepko R, Bodzenta-Lukaszyk A.

Int Arch Allergy Immunol. 2012;159(2):121-9. doi: 10.1159/000335674. Epub 2012 May 30.

39.

Bronchial hyperresponsiveness and airway inflammation in patients with seasonal allergic rhinitis.

Skiepko R, Zietkowski Z, Tomasiak-Lozowska MM, Tomasiak M, Bodzenta-Lukaszyk A.

J Investig Allergol Clin Immunol. 2011;21(7):532-9.

40.

Allergen challenge differentially affects the number of circulating monocyte subsets.

Kowal K, Moniuszko M, Dabrowska M, Bodzenta-Lukaszyk A.

Scand J Immunol. 2012 May;75(5):531-9. doi: 10.1111/j.1365-3083.2012.02685.x.

41.

Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.

Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A.

Adv Med Sci. 2011;56(2):318-22. doi: 10.2478/v10039-011-0024-0.

PMID:
21940268
42.
43.

[Statins and asthma].

Pawlak J, Ziętkowski Z, Bodzenta-Łukaszyk A.

Postepy Hig Med Dosw (Online). 2011 Mar 25;65:177-89. Polish.

44.

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.

Kowal K, Moniuszko M, Zukowski S, Bodzenta-Lukaszyk A.

Folia Histochem Cytobiol. 2010 Dec;48(4):518-23. doi: 10.2478/v10042-010-0075-2.

45.

Eotaxin in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction.

Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Zietkowska E, Bodzenta-Lukaszyk A.

Respiration. 2011;82(2):169-76. doi: 10.1159/000323180. Epub 2011 Jan 21.

46.

Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler.

Bodzenta-Lukaszyk A, Pulka G, Dymek A, Bumbacea D, McIver T, Schwab B, Mansikka H.

Respir Med. 2011 May;105(5):674-82. doi: 10.1016/j.rmed.2010.11.011. Epub 2010 Dec 31.

47.

Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients.

Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, Zietkowska E, Bodzenta-Lukaszyk A.

Respir Res. 2010 Aug 12;11:110. doi: 10.1186/1465-9921-11-110.

48.

RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.

Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Lenczewska D, Bodzenta-Lukaszyk A.

Int Arch Allergy Immunol. 2011;154(1):25-32. doi: 10.1159/000319205. Epub 2010 Jul 24.

PMID:
20664274
49.

Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma.

Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A.

Respiration. 2010;80(6):534-42. doi: 10.1159/000317137. Epub 2010 Jun 26.

50.

Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.

Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, Birnbaum J, Bodzenta-Lukaszyk A, Bonifazi F, Bucher C, Campi P, Darsow U, Egger C, Haeberli G, Hawranek T, Kucharewicz I, Küchenhoff H, Lang R, Quercia O, Reider N, Severino M, Sticherling M, Sturm GJ, Wüthrich B; European Academy of Allergy and Clinical Immunology Interest Group.

J Allergy Clin Immunol. 2010 Jul;126(1):105-11.e5. doi: 10.1016/j.jaci.2010.04.025. Epub 2010 Jun 12.

PMID:
20542320

Supplemental Content

Loading ...
Support Center